Explore emerging strategies to improve clinical outcomes and slow disease progression in patients with diabetic kidney ...

With almost half of American adults living with high blood pressure, it makes sense that you'd want every possible tool in ...

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...

The George Institute for Global Health is thrilled to congratulate doctoral researcher Dr Lauren Heath on receiving a ...

VESALIUS-CV data supported evolocumab reducing MACE in high-risk primary prevention diabetes over 4.8 years, reinforcing the ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), ...

Scientists have now developed a new drug called baxdrostat, which offers hope by lowering blood pressure in these tough cases ...

A new pill called baxdrostat is showing strong results in lowering dangerously high blood pressure in people who don’t ...

This article is part of “Innovations In: Kidney Disease,” an editorially independent special report that was produced with financial support from Vertex. More than one in seven people in the U.S. have ...

This article is part of “Innovations In: Kidney Disease,” an editorially independent special report that was produced with financial support from Vertex. The global burden of chronic kidney disease ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...

Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16. Several years ago, nephrologists attempted a first-of-its-kind effort ...